Form D · Pharmaceuticals
Dauntless 2, Inc.
San Diego, CA · CIK 0001693654
Offering snapshot reported Jan 6, 2017 · SEC filing
- Reported sold
- $6.05M Offering amount: $18.1M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 15, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 6, 2017 | Initial | $6,053,916 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-277776
Total Amount Sold includes value of cancelled indebtedness formerly held by certain purchasers in the aggregate principal and interest amount of $1,053,917.
Source: Form D, filed Jan 6, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Kabakoff | Director |
| Joel Martin | Director, Executive |
| Michael Powell | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
12390 El Camino Real, Suite 170
San Diego, CA, 92130
San Diego, CA, 92130